Oncotarget

Meta-Analysis:

Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers

Yijun Tian, Qian Liu, Kongju Wu, Qian Chu, Yuan Chen and Kongming Wu _

PDF  |  HTML  |  Order a Reprint

Oncotarget. 2017; 8:62330-62338. https://doi.org/10.18632/oncotarget.17499

Metrics: HTML 1188 views  |   ?  


Abstract

Yijun Tian1, Qian Liu1, Kongju Wu2, Qian Chu1, Yuan Chen1 and Kongming Wu1

1Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China

2Medical School of Pingdingshan University, Pingdingshan, P.R. China

Correspondence to:

Kongming Wu, email: kmwu@tjh.tjmu.edu.cn

Keywords: nedaplatin, non-small cell lung cancer, squamous cell lung cancer, chemotherapy

Received: June 19, 2016    Accepted: April 17, 2017    Published: April 28, 2017

ABSTRACT

Non-small cell lung cancer (NSCLC) consists of several subtypes, including adenocarcinoma, squamous cell lung cancer, large cell lung cancer, and other rarer types. Platinum-based regimens are currently the standard for treatment of advanced NSCLC. Nedaplatin is reportedly associated with a high response rate in squamous cell lung cancer. However, the relevant studies are small and mainly descriptive. The purpose of this meta-analysis was therefore to compare the efficacy of nedaplatin in squamous cell lung cancer with that in non-squamous cell lung cancer. Studies concerning nedaplatin-based regimens in NSCLC patients were retrieved from PubMed and EMBASE. The response rate for nedaplatin-based regimens in squamous cell lung cancer (ORR: 55.6%, 95% CI: 52.5-58.7%) was higher (OR: 1.55, 95% CI: 1.17-2.05) than that for non-squamous cell lung cancer (ORR: 34.4%, 95% CI: 32.3-36.5%). In addition, Taxane plus nedaplatin produced a longer overall and progress-free survival than CPT-11 or gemcitabine plus nedaplatin. To verify these findings, future well-controlled clinical studies will be needed.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17499